Navigation Links
Convoy Therapeutics Appoints Clinical Advisory Board
Date:11/5/2013

Oro Valley, Arizona (PRWEB) November 05, 2013

Convoy Therapeutics, a late pre-approval stage dermatology company, announced the creation of its clinical advisory board (CAB) today. The Convoy CAB is composed of six distinguished experts whose mission will be to advise Convoy Therapeutics on the development of robust clinical strategies and effective approaches to support commercialization for Convoy’s pipeline of new products powered by Convoy’s patented Skin Penetrating And Cell Entering peptide dermal delivery technology, “SPACE”.

Convoy’s President and CEO, John Muraski, Ph.D., said, “The creation of our Clinical Advisory Board is an essential step for Convoy. Establishing a robust clinical strategy with the advice of these experts is critical to link our technology and innovation with solutions for unmet medical needs and commercialization optimization.”

Composition of the Clinical Advisory Board

Dr. Alan Menter
Dr. Menter is Chairman of the Division of Dermatology at Baylor University Medical Center and head of Psoriasis research at the Baylor Research Institute. He is also Past President of International Psoriasis Council. After obtaining his medical degree from the University of Witwatersrand in Johannesburg and residency in dermatology at the University of Pretoria in South Africa, Dr. Menter completed fellowships at Guy’s Hospital and St. John’s Hospital for Diseases of the Skin, in London. Dr. Menter then came to the United States and completed a fellowship in dermatology at Southwestern Medical School in Dallas and was Board Certified in dermatology in 1977.

Dr. Mark Lebwohl
Dr. Lebwohl is a professor and chairman of the Department of Dermatology at The Mount Sinai School of Medicine. He is also Chairman of the Medical Board of the National Psoriasis Foundation and a current member of the Board of Directors of the American Academy of Dermatology. Dr. Lebwohl graduated from Harvard Medical School in 1978 and completed residencies in internal medicine and dermatology at Mount Sinai.

Dr. John Y. M. Koo
Dr. Koo is a professor of Clinical Dermatology at the University of California at San Francisco (UCSF) School of Medicine and is Director of the Psoriasis, Phototherapy, and Skin Treatment Clinic. He is a graduate of Harvard Medical School and a Harvard National Scholar. Dr. Koo completed an internship and residency in psychiatry at the University of California, Los Angeles.

Dr. Alice Gottlieb
Dr. Gottlieb is a professor of Dermatology at Tufts University School of Medicine, Chair of Dermatology and Dermatologist-in-Chief of the hospital at Tufts Medical Center. She is an internationally recognized leader in the fields of psoriasis and psoriatic arthritis and is currently a member of the Board of Directors of the American Academy of Dermatology. Dr. Gottlieb received her medical degree from Cornell University and a Ph.D. in Immunology from the Rockefeller University.

Dr. Craig Leonardi
Dr. Leonardi is a Clinical Professor of Dermatology at St. Louis University Medical School in St. Louis, Missouri. He is a founding member and current Treasurer of the International Psoriasis Council. Dr. Leonardi has been involved in more than 190 clinical trials and has published more than 200 original articles. He graduated from the University of Miami School of Medicine and completed residencies in pediatrics and dermatology at the University of Miami/Jackson Memorial Hospital.

Dr. David Pariser
Dr. Pariser is a professor at the Eastern Virginia Medical School Department of Dermatology. He is Past President of the American Academy of Dermatology and is currently on the Board of Directors. He is regularly involved in clinical research and is on the forefront of pharmaceutical development in the field of Psoriasis. Dr. Pariser is a graduate of the Medical College of Virginia, and received his dermatology training at the University of Miami/Jackson Memorial Hospital. He is also Board Certified in dermatology.

About Convoy Therapeutics
Convoy Therapeutics is a late stage dermatology company using its proprietary platform of peptides, including the SPACETM peptide, to enable or enhance delivery and retention of actives in the skin. The basic technology was originally discovered by Professor Samir Mitragotri at the University of California at Santa Barbara and includes a variety of peptides and formulation techniques, which when combined, provide exceptional enhancement of macromolecule penetration into the skin.

For further information on Convoy Therapeutics please visit http://www.convoytx.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11300954.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Convoy Therapeutics Granted Patent for Proprietary SPACE Technology
2. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
3. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
4. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
5. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
6. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
7. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
8. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
9. PTC Therapeutics Expands Management Team
10. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
11. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):